We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

New age boss

26 September 2018 By Robert Cyran

The drug maker has waived its retirement age so Kenneth Frazier can stay on as boss. He has justified the move by prioritizing R&D, fighting drug lawsuits, and making smart hires. The chance-filled path of hit cancer drug Keytruda also helped. And 65 is no longer a sell-by date.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)